Skip to main content
Premium Trial:

Request an Annual Quote

Trying Not to Encroach on NIH Mission, Genomes to Life Changes Name

NEW YORK, May 20 (GenomeWeb News) - The Department of Energy's Genomes to Life program has changed its name to Genomics: GTL, according to a DOE official.


Ari Patrinos, director of biological and environmental research at the DOE, said the project changed its name after members of a congressional subcommittee that oversees the US National Institutes of Health voiced concern that the original name may lead people to infer that the program deals with human biology - traditionally an NIH endeavor, and not a DOE responsibility.


Patrinos stressed that the overall goals and mission of Genomes to Life have not changed. He said the name change began several months ago, and that it is a gradual process. "It hasn't been an abrupt change," he said.


The name still appears in many places -- for instance, the Genomics: GTL website address still reads -- and "a lot of people still use" the old name, said Patrinos.


Some members of the House Energy and Commerce Committee, an authorizing group that has jurisdiction over NIH programs, "were concerned that the name of the [Genomes to Life] program made it sound, at least to them, that it was an NIH program," Patrinos told GenomeWeb News ­this week. "For the purposes of clarification, they encouraged us to change the name." The DOE is overseen by the House Energy and Water Committees.


He said the new name is a "more neutral term that does not necessarily have any particular affiliation with a specific agency."


Patrinos said the Genomes to Life name gave members of the commission "the impression that it had to do with human biology. ... The GTL program is focused on energy applications" such as bioremediation, clean energy production, and carbon sequestration.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.